Study of MK-6552 in Participants With Narcolepsy Type 1 (MK-6552-004)

Summary

The purpose of this study was to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of MK-6552 in participants with Narcolepsy Type 1 (NT1). The effect of single MK-6552 doses were assessed initially under open-label conditions to evaluate the safety, tolerability, and PK of MK-6552. The effect of repeated MK-6552 doses (every 8 hours \[q8h\] for 7 days) were assessed under double-blind and placebo-controlled conditions.

Timeline

Start

2024-01-24

Primary completion

2024-10-23

Completion

2024-10-23

Drugs

Indications